Evidence map›Paper›PMID 41044644›Full record

ReviewMolecular cancer2025

Non-coding RNAs in gastric cancer: mechanisms and therapeutic prospects.

Zhifei Han, Wenjuan Liu, Yigao Zhu, Yinggang Sun, Dong Sun, Ruyue Jia, Yanting Yang, Houbao Qi, Long Zhang, Yanfei Huo and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Role of histone modifications in gastric cancer (Review).International journal of oncology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhifei Han *Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Wenjuan Liu *Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Yigao ZhuSchool of Life Sciences, Shandong First Medical University, Shandong Academy of Medical Sciences, Taian, Shandong Province, 271021, China.
Yinggang SunDepartment of Gastrointestinal Surgery, The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Jinan, 250031, Shandong, China.
Dong SunDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Ruyue JiaShandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Yanting YangSchool of Life Sciences, Shandong First Medical University, Shandong Academy of Medical Sciences, Taian, Shandong Province, 271021, China.
Houbao QiSchool of Life Sciences, Shandong First Medical University, Shandong Academy of Medical Sciences, Taian, Shandong Province, 271021, China.
Long ZhangShandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Yanfei HuoShandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Nasha Zhang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, 250117, China. wownseva@126.com.
Jie ChaiDepartment of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China. jchai@sdfmu.edu.cn.
Ming YangShandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China. yangm@sdu.edu.cn.

Funding

National Natural Science Foundation of China 82103291National Natural Science Foundation of China 82372760Shandong Provincal Natural Science Foundation ZR2022LZL002
6 · The paper itself

Abstract

Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. It is associated with high molecular and phenotypic heterogeneity. Early-stage gastric cancer can be treated with endoscopic resection and surgery, whereas at its advanced stage, sequential chemotherapy presents the only treatment option, which starts with first-line platinum and fluoropyrimidine-based dual drugs, supporting a median survival period of less than one year. Targeted monoclonal antibodies approved for the treatment of gastric cancer are effective for a limited subset of patients. Furthermore, painless and precise markers for the early detection of gastric cancer and new targets for its treatment are unavailable. Interestingly, many non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), play key roles in the development of gastric cancer. Multiple pieces of evidence suggest that ncRNAs play a crucial role in the treatment of gastric cancer using chemotherapy and targeted therapy drugs. In this article, we systematically reviewed the important roles of ncRNAs in chemotherapy resistance, immune escape, metabolism, and angiogenesis of gastric cancer, and systematically elucidated the relevant molecular mechanisms. In addition, we also proposed the potential clinical significance of ncRNA as a new therapeutic target and prognostic biomarker for gastric cancer.

Indexed as

Biomarkers, TumorRNA, UntranslatedStomach NeoplasmsAnimalsDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyPrognosisRNA, CircularBiomarkers, TumorRNA, CircularRNA, UntranslatedBiomarkerChemotherapyDrug resistanceGastric cancerNon-coding RNAs

Identifiers

PMID41044644
PMCPMC12495625

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.